Rate of myocarditis higher after receipt of mRNA-1273, particularly for younger men (younger than 40 years)<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Nov. 9, 2022 (HealthDay News) — The rates of myocarditis and pericarditis are increased after receipt of the second dose of mRNA-1273 versus BNT162b2, according to a study published in the Nov. 15 issue of the Journal of the American College of Cardiology<\/em>.<\/p>\n Zaeema Naveed, M.B.B.S., Ph.D., from the British Columbia Center for Disease Control in Vancouver, Canada, and colleagues compared the risks for myocarditis, pericarditis, and myopericarditis related to BNT162b2 and mRNA-1273 using data from the British Columbia COVID-19 Cohort. The association between exposure to the second dose of an mRNA vaccine and a diagnosis of myocarditis, pericarditis, or myopericarditis during a hospitalization or an emergency department visit within 21 days was examined.<\/p>\n The researchers found that the rates of myocarditis and pericarditis were higher for mRNA-1273 than BNT162b2 (rates, 35.6 and 22.9 versus 12.6 and 9.4 per million second doses, respectively). Significantly higher odds of myocarditis, pericarditis, and myopericarditis were seen for mRNA-1273 versus BNT162b2 (adjusted odds ratios, 2.78, 2.42, and 2.63, respectively). A stronger association between mRNA-1273 and myocarditis was seen for men and for the younger age group (younger than 40 years; adjusted odds ratios, 3.21 and 5.09, respectively).<\/p>\n “Our findings have implications for strategizing the rollout of mRNA vaccines, which should also consider the self-limiting and mild nature of most myocarditis events, benefits provided by vaccination, higher effectiveness of the Moderna vaccine against infection and hospitalization [found in prior studies], and the apparent higher risk of myocarditis following COVID-19 infection than with mRNA vaccination,” Naveed said in a statement.<\/p>\n One author disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n